Cxotalk: Leadership, Innovation, Disruption

#ai #generativeai #drugdiscovery #pharma In this episode of CXOTalk, we have the pleasure of speaking with Dr. Alex Zhavoronkov, the founder and CEO of Insilico Medicine.Insilico Medicine uses artificial intelligence to enhance drug discovery. By combining generative adversarial networks (GANs), reinforcement learning, and other AI techniques, Insilico streamlines the design, synthesis, and testing of new molecules. Their approach has garnered attention, raising $400 million in funding so far.Dr. Zhavoronkov shares insights into Insilico's goals, such as the accelerated development and testing of small molecules targeting specific diseases. We also explore how their software impacts pharmaceutical R&D by enabling researchers to investigate new targets, design molecules with certain properties, and potentially predict the outcomes of clinical trials.Join us as we discuss the evolving landscape of pharmaceuticals and how generative AI can help discover new treatments for chronic diseases and promote a healt